BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Oppenheimer 33rd Annual Healthcare Conference:
Location: | Virtual |
Format: | Fireside chat and one-on-one meetings |
Date: | March 13-15, 2023 |
Fireside chat: | March 13, 10:00am ET |
Presenter: | Spiro Rombotis |
Webcast: | Link |
35th Annual Roth Conference:
Location: | Dana Point, CA |
Format: | Fireside chat and one-on-one meetings |
Date: | March 12-14, 2023 |
Fireside chat: | March 13, 3:00pm PT |
Presenter: | Paul McBarron |
Webcast: | Link |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Contacts
Company: | Paul McBarron, (908) 517-7330, This email address is being protected from spambots. You need JavaScript enabled to view it. |
Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, This email address is being protected from spambots. You need JavaScript enabled to view it. |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
Last Trade: | US$1.02 |
Daily Change: | 0.01 0.99 |
Daily Volume: | 29,797 |
Market Cap: | US$2.010M |
August 14, 2024 May 14, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB